Fuxe / Calne Dopaminergic Ergot Derivatives and Motor Function

Proceedings of an International Symposium Held in the Wenner-Gren Center, Stockholm, July 24-25, 1978
1. Auflage 2013
ISBN: 978-1-4831-6097-9
Verlag: Elsevier Science & Techn.
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 462 Seiten, Web PDF

Dopaminergic Ergot Derivatives and Motor Function is a collection of papers from the proceedings of an international symposium of the same topic, held in Stockholm on July 24-25, 1978. This collection of papers covers laboratory studies on different subjects such as the anatomy, physiology, biochemistry, and pharmacology of dopaminergic pathways of the brain. This book also discusses clinical research dealing on dopaminergic receptors observed in Parkinsonism and in Huntington's disease. One paper reviews the neural circuitry of the basal ganglia as it is the part of the brain that is first and foremost involved in skeletomuscular mechanisms. Another paper deals with the different groups of ergot derivatives and their structure-activity relationships. The book also addresses the therapeutic activity and toxicity made during these observations. The text then discusses the psychiatric reaction to ergot derivatives, including LSD-induced hallucinations. Another paper examines the effects of dopaminergic ergots on the anterior pituitary function that is limited to the control of prolactin secretion during chronic therapy. This book is valuable to microbiologists, microchemists, and laboratory researchers and scientists dealing with neuro-functions and the brain.

Autoren/Hrsg.

Fuxe, Kjell

Calne, Donald B.

Inhaltsverzeichnis

1;Front Cover;1
2;Dopaminergic Ergot Derivatives and Motor Function;4
3;Copyright Page;5
4;Table of Contents;6
5;LIST OF PARTICIPANTS;10
6;PREFACE;14
7;SECTION I: DOPAMINERGIC MECHANISMS;16
7.1;CHAPTER 1. THE ANATOMY OF THE EXTRAPYRAMIDAL SYSTEM;18
7.1.1;INTRODUCTION;18
7.1.2;STRIATUM;18
7.1.3;GLOBUS PALLIDUS;24
7.1.4;SUBTHALAMIC NUCLEUS;27
7.1.5;SUBSTANTIA NIGRA;28
7.1.6;COMMENT;30
7.1.7;ACKNOWLEDGEMENTS;31
7.1.8;REFERENCES;32
7.2;CHAPTER 2. CHEMICAL ASPECTS OF ERGOT DERIVATIVES WITH CENTRAL DOPAMINERGIC ACTIVITY;38
7.2.1;ABSTRACT;38
7.2.2;INTRODUCTION;38
7.2.3;ERGOPEPTINES, ERGOLINES, CLAVINES;38
7.2.4;STRUCTURE-ACTIVITY RELATIONSHIP;43
7.2.5;REFERENCES;46
7.3;CHAPTER 3. BIOCHEMICAL ANATOMY OF THE EXTRAPYRAMIDAL SYSTEM;48
7.3.1;NEUROANATOMY OF THE EXTRAPYRAMIDAL SYSTEM;48
7.3.2;THE STRIATUM AND PALLIDUM;49
7.3.3;THE SUBSTANTIA NIGRA;52
7.3.4;INTERACTIONS AMONG VARIOUS POPULATIONS OF NEURONS;53
7.3.5;CONCLUDING REMARKS;53
7.3.6;REFERENCES;54
7.4;CHAPTER 4. PATHOPHYSIOLOGY OF MOTOR PERFORMANCE IN PARKINSON'S DISEASE;60
7.4.1;INTRODUCTION;60
7.4.2;STUDIES OF REACTION TIME AND SPEED OF MOVEMENT;60
7.4.3;RESPONSES TO LIMB DISPLACEMENT IN PD;65
7.4.4;MECHANISMS UNDERLYING TREMOR;68
7.4.5;MECHANISMS UNDERLYING POVERTY OF MOVEMENT;70
7.4.6;ACKNOWLEDGEMENT;71
7.4.7;REFERENCES;72
7.5;CHAPTER 5. DOPAMINERGIC ERGOTS: DRUGS WHICH DISCRIMINATE BETWEEN THE MULTIPLE CLASSES OF DOPAMINE RECEPTORS;76
7.5.1;INTRODUCTION;76
7.5.2;BIOCHEMICAL SPECIFICITY OF DOPAMINERGIC ERGOTS;79
7.5.3;SUMMARY AND CONCLUSIONS;83
7.5.4;REFERENCES;84
7.6;CHAPTER 6. DOPAMINE RECEPTORS AND PHOSPHODIESTERASES;88
7.6.1;Relationship between dopamine receptors and phosphodiesterases;88
7.6.2;Effect of phosphodiesterase inhibitors on dopaminergic mechanisms;90
7.6.3;Effect of phosphodiesterase inhibitors on rotation behaviour;91
7.6.4;Interaction of the phosphodiesterase inhibitors with adenosine;92
7.6.5;References;95
7.7;CHAPTER 7. SPECIFICITY OF AGONISTS AND ANTAGONISTS AT MODEL RECEPTORS FOR DOPAMINE AND OCTOPAMINE;100
7.7.1;ABSTRACT;100
7.7.2;INTRODUCTION;101
7.7.3;RESULTS;101
7.7.4;REFERENCES;113
7.8;CHAPTER 8. INFLUENCE OF ERGOT DERIVATIVES ON THE DIFFERENT TYPES OF DOPAMINE RECEPTORS AND ON OTHER AMINE RECEPTORS IN PRIMATE BRAIN;116
7.8.1;ABSTRACT;116
7.8.2;INTRODUCTION;117
7.8.3;METHODS;117
7.8.4;RESULTS;117
7.8.5;CONCLUSIONS;126
7.8.6;REFERENCES;127
7.9;CHAPTER 9. DOP AMINE AND HUNTINGTON'S DISEASE: ASSESSMENT USING THE KAINIC ACID MODEL;130
7.9.1;METHODS;130
7.9.2;RESULTS;132
7.9.3;DISCUSSION;135
7.9.4;SUMMARY;139
7.9.5;ACKNOWLEDGEMENTS;140
7.9.6;REFERENCES;140
8;SECTION II: DOPAMINERGIC AGONISM OF ERGOT DERIVATIVES;142
8.1;CHAPTER 10. NEUROPHARMACOLOGY OF ERGOT DERIVATIVES;144
8.1.1;ABSTRACT;144
8.1.2;INTRODUCTION;144
8.1.3;BIOCHEMICAL STUDIES;145
8.1.4;FUNCTIONAL STUDIES;147
8.1.5;REFERENCES;153
8.2;CHAPTER 11. ACTIONS OF ERGOT DERIVATIVES AT DOPAMINE SYNAPSES;156
8.2.1;EFFECTS OF ERGOT DRUGS ON 3H-SPIROPERIDOL BINDING IN STRIATUM OF EXPERIMENTAL RATS;158
8.2.2;EFFECTS OF ERGOT DRUGS ON ADENYLATE CYCLASE ACTIVITY;160
8.2.3;BEHAVIOURAL ACTIONS OF DOPAMINERGIC ERGOT DERIVATIVES;164
8.2.4;COMPARISONS BETWEEN THE EFFECTS OF DIFFERENT TYPES OF D0PAMINERGIC ERGOT DERIVATIVES ON CENTRAL D0PAMINERGIC MECHANISMS;165
8.2.5;EFFECTS OF ERGOT DRUGS ON LIMBIC DA RECEPTORS AND CENTRAL 5-HT RECEPTORS;167
8.2.6;EFFECTS OF ERGOT DRUGS ON CENTRAL a-ADRENERGIC RECEPTORS;168
8.2.7;ACKNOWLEDGEMENTS;169
8.2.8;REFERENCES;171
8.3;CHAPTER 12. DOPAMINERGIC ERGOT DERIVATIVES: SELECTIVE AGONISTS OF A NEW CLASS OF DOPAMINE RECEPTORS?;174
8.3.1;EFFECTS ON CELL-EKEE PREPARATIONS;175
8.3.2;EFFECTS ON SLICES OF NEOSTIATUM;178
8.3.3;EFFECTS ON IN VIVO PRODUCTION OF STRIATAL CYCLIC AMP AND CEREBELLAR CYCLIC GMP;180
8.3.4;DISCUSSION AND CONCLUSIONS;182
8.3.5;REFERENCES;184
8.4;CHAPTER 13. ACTION OF ERGOT DOPAMINERGIC AGONISTS ON MONOAMINE SYNTHESIS IN RAT BRAIN;188
8.4.1;CATECHOLAMINE SYNTHESIS IN RAT BRAIN;188
8.4.2;5-HT SYNTHESIS;192
8.4.3;CATECHOLAMINE AND 5-HT SYNTHESIS AFTER PRETREATMENT WITH RESERPINE;193
8.4.4;ACTION OF ERGOT DERIVATIVES AT PRESYNAPTIC D0PAMINE RECEPTORS;195
8.4.5;CONCLUSIONS;198
8.4.6;REFERENCES;199
8.5;CHAPTER 14. BEHAVIOURAL EFFECTS OF ERGOT DRUGS;202
8.5.1;ABSTRACT;202
8.5.2;INTRODUCTION;202
8.5.3;METHODS;203
8.5.4;RESULTS;206
8.5.5;DISCUSSION;215
8.5.6;REFERENCES;218
8.6;CHAPTER 15. EFFECTS OF ERGOLINES ON DOPAMINERGIC AND SEROTONERGIC SINGLE UNIT ACTIVITY;222
8.6.1;INTRODUCTION;222
8.6.2;EFFECTS OF LISURIDE AND LERGOTRILE ON DOPAMINERGIC UNIT ACTIVITY;223
8.6.3;EFFECTS ON SEROTONERGIC UNIT ACTIVITY;231
8.6.4;CORRELATIONS WITH BEHAVIORAL, BIOCHEMICAL, AND CLINICAL OBSERVATIONS;232
8.6.5;ACKNOWLEDGEMENT;234
8.6.6;REFERENCES;234
8.7;CHAPTER 16. DOPAMINERGIC AND SEROTONERGIC EFFECTS OF ERGOT DRUGS;238
8.7.1;INTRODUCTION;238
8.7.2;METHODS;239
8.7.3;RESULTS;240
8.7.4;DISCUSSION;247
8.7.5;REFERENCES;249
8.8;CHAPTER 17. PHARMACOLOGICAL EFFECTS OF LISURIDE IN RODENTS MEDIATED BY DOPAMINERGIC RECEPTORS: MECHANISM OF ACTION AND INFLUENCE OF CHRONIC TREATMENT WITH LISURIDE;252
8.8.1;MATERIAL AND METHODS;254
8.8.2;RESULTS;256
8.8.3;DISCUSSION;263
8.8.4;Bibliography;264
8.9;CHAPTER 18. THE DOPAMINEPHILLIC PROPERTIES OF ERGOLINE DERIVATIVES;268
8.9.1;INTRODUCTION;268
8.9.2;DISCUSSION;272
8.9.3;SUMMARY;274
8.9.4;REFERENCES;274
9;SECTION III: THERAPEUTIC ACTIONS OF ERGOT DERIVATIVES;276
9.1;CHAPTER 19. CLINICAL PHARMACOLOGY OF ERGOTS;278
9.2;CHAPTER 20. ACTIONS OF BROMOCRIPTINE IN THE SHY-DRAGER AND STEELE - RICHARDSON - OLSZEWSKI SYNDROMES;286
9.2.1;INTRODUCTION;286
9.2.2;METHODS;286
9.2.3;RESULTS;288
9.2.4;DISCUSSION;294
9.2.5;CONCLUSION;296
9.2.6;ACKNOWLEDGEMENT;296
9.2.7;REFERENCES;296
9.3;CHAPTER 21. MODIFICATION OF THE "ON-OFF" EFFECT WITH BROMOCRIPTINE AND LERGOTRILE;300
9.3.1;ABSTRACT;300
9.3.2;INTRODUCTION;300
9.3.3;METHODS;300
9.3.4;RESULTS;301
9.3.5;DISCUSSION;302
9.3.6;ACKNOWLEDGEMENT;303
9.3.7;REFERENCES;309
9.4;CHAPTER 22. BROMOCRIPTINE COMPARED WITH LEVODOPA IN PARKINSONISM;312
9.4.1;REFERENCES;316
9.5;CHAPTER 23. ROLE OF BROMOCRIPTINE IN THE TREATMENT OF PARKINSONISM;318
9.5.1;ABSTRACT;318
9.5.2;INTRODUCTION;318
9.5.3;METHODS;318
9.5.4;RESULTS;321
9.5.5;DISCUSSION;325
9.5.6;ACKNOWLEDGEMENTS;326
9.5.7;REFERENCES;326
9.6;CHAPTER 24. DOSE-DEPENDENT LOCOMOTOR EFFECTS OF BROMOCRIPTINE IN ANIMALS AND MAN —ARE SOME OF ITS ACTIONS DUE TO METABOLITES?;328
9.6.1;ABSTRACT;328
9.6.2;INTRODUCTION;328
9.6.3;LOCOMOTOR EFFECTS IN ANIMALS;328
9.6.4;LOCOMOTOR EFFECTS IN MAN;329
9.6.5;PRE- AND POST-SYNAPTIC ACTIONS OF BROMOCRIPTINE;330
9.6.6;ARE BROMOCRIPTINE'S ACTIONS ON DOPAMINE RECEPTORS DUE TO METABOLITES?;331
9.6.7;ACKNOWLEDGEMENTS;332
9.6.8;REFERENCES;332
9.7;CHAPTER 25. RELATIONSHIP BETWEEN BRAIN DOPAMINE TURNOVER AND THE THERAPEUTIC RESPONSE TO BROMOCRIPTINE;334
9.7.1;ABSTRACT;334
9.7.2;INTRODUCTION;334
9.7.3;PATIENTS AND METHODS;334
9.7.4;RESULTS;335
9.7.5;DISCUSSION;337
9.7.6;ACKNOWLEDGEMENT;338
9.7.7;REFERENCES;338
9.8;CHAPTER 26. BROMOCRIPTINE AS AN ADJUVANT TO LEVODOPA;344
9.8.1;ABSTRACT;344
9.8.2;INTRODUCTION;344
9.8.3;METHODS;344
9.8.4;RESULTS;345
9.8.5;BENEFICIAL EFFECTS;345
9.8.6;SIDE EFFECTS;347
9.8.7;DISCUSSION;348
9.8.8;REFERENCES;349
9.9;CHAPTER 27. ERGOT DERIVATIVES WITHOUT LEVODOPA IN PARKINSONISM;352
9.9.1;ABSTRACT;352
9.9.2;INTRODUCTION;352
9.9.3;PATIENTS AND METHODS;352
9.9.4;RESULTS;353
9.9.5;DISCUSSION;353
9.9.6;REFERENCES;354
9.10;CHAPTER 28. CLINICAL OBSERVATIONS WITH BROMOCRIPTINE IN PARKINSONISM;358
9.10.1;INTRODUCTION;358
9.10.2;DOUBLE-ELIND CROSS-OVER TRIAL;358
9.10.3;BROMOCRIPTINE WITH OR WITHOUT LEVODOPA;359
9.10.4;PLASMA CONCENTRATION OF BROMOCRIPTINE;361
9.10.5;CONCLUSIONS;361
9.10.6;ACKNOWLEDGEMENT;361
9.10.7;REFERENCES;361
9.11;CHAPTER 29. ERGOT DERIVATIVES IN THE TREATMENT OF PSYCHOTIC AND HYPERKINETIC DISORDERS;364
9.11.1;INTRODUCTION;364
9.11.2;APOMORPHINE;365
9.11.3;ERGOT DERIVATIVES;367
9.11.4;CF 25-397;370
9.11.5;CONCLUSIONS;370
9.11.6;REFERENCES;372
9.12;CHAPTER 30. ERGOT DERIVATIVES IN DYSKINETIC AND DYSTONIC DISORDERS;376
9.12.1;SUMMARY;376
9.12.2;INTRODUCTION;376
9.12.3;PATIENTS AND METHODS;377
9.12.4;CLINICAL RESULTS;379
9.12.5;DISCUSSION;381
9.12.6;REFERENCES;382
10;SECTION IV: ADVERSE REACTIONS OF ERGOT DERIVATIVES;386
10.1;CHAPTER 31. TOXICITY OF ERGOT ALKALOIDS;388
10.1.1;INTRODUCTION;388
10.1.2;TYPES OF ERGOT TOXICITY;388
10.1.3;RELATION OF TOXIC EFFECTS TO KNOWN PHARMACODYNAMIC ACTIONS;390
10.1.4;ANIMAL TOXICITY STUDIES;392
10.1.5;BROMOCRIPTINE TOXICITY;393
10.1.6;CONCLUSIONS;394
10.1.7;REFERENCES;394
10.2;CHAPTER 32. CARDIOVASCULAR EFFECTS OF ERGOT DERIVATIVES IN MAN;396
10.2.1;INTRODUCTION;396
10.2.2;BLOOD PRESSURE AND HEART RATE;396
10.2.3;EFFECTS ON THE PERIPHERAL CIRCULATION;397
10.2.4;INTERACTIONS WITH BIOGENIC AMINES;404
10.2.5;REFERENCES;405
10.3;CHAPTER 33. CARDIOVASCULAR REACTIONS TO BROMOCRIPTINE;410
10.3.1;ABSTRACT;410
10.3.2;INTRODUCTION;410
10.3.3;CONCLUSIONS;416
10.3.4;ACKNOWLEDGEMENTS;416
10.3.5;REFERENCES;416
10.4;CHAPTER 34. PSYCHIATRIC REACTION TO ERGOT DERIVATIVES;420
10.4.1;REFERENCES;427
10.5;CHAPTER 35. THE HEPATOTOXICITY OF ERGOT ALKALOIDS;430
10.5.1;ABSTRACT;430
10.5.2;INTRODUCTION;430
10.5.3;METHODS;431
10.5.4;RESULTS;431
10.5.5;DISCUSSION;439
10.5.6;ACKNOWLEDGEMENTS;440
10.5.7;REFERENCES;442
10.6;CHAPTER 36. ENDOCRINE EFFECTS OF DOPAMINERGIC ERGOT ALKALOIDS —TOXICOLOGICAL IMPLICATIONS;446
10.6.1;ABSTRACT;446
10.6.2;INTRODUCTION;446
10.6.3;ANTERIOR PITUITARY HORMONE SECRETION AND EFFECTS OF DOPAMINE AGONISTS;446
10.6.4;COMPARISON OF THE MENSTRUAL CYCLE AND ESTRUS CYCLE OF THE RAT;449
10.6.5;INVOLUTION OF REPRODUCTIVE FUNCTION IN WOMEN AND FEMALE RATS;450
10.6.6;THE EFFECTS OF BROMOCRIPTINE ON REPRODUCTIVE FUNCTION IN THE FEMALE;451
10.6.7;THE ENDOMETRIAL STUDIES IN WOMEN;451
10.6.8;DISCUSSION;453
10.6.9;REFERENCES;454
11;SUBJECT INDEX;458